loading page

A literature review on the therapeutic applicability of cannabidiol in epilepsy, multiple sclerosis and Parkinson's disease
  • +2
  • Maria de Fátima dos Santos Sampaio,
  • Yara Bezerra de Paiva,
  • Tuane Bazanella Sampaio,
  • Messias Gonzaga Pereira,
  • Norberto Cysne Coimbra
Maria de Fátima dos Santos Sampaio
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto
Author Profile
Yara Bezerra de Paiva
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto
Author Profile
Tuane Bazanella Sampaio
Universidade Federal de Santa Maria
Author Profile
Messias Gonzaga Pereira
Universidade Estadual do Norte Fluminense Darcy Ribeiro
Author Profile
Norberto Cysne Coimbra
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto

Corresponding Author:[email protected]

Author Profile

Abstract

Neurodegenerative diseases have complex etiologies, however, neuroinflammation and oxidative stress are important markers in this pathogenesis and, in this sense, cannabinoids, especially CBD, have been identified as potential therapeutics for playing a neuroprotective role. Studies have demonstrated the neuroprotective effect of cannabinoids and derivatives of Cannabis sativa L in diseases of the central nervous system due to their interaction with the endocannabinoid system through receptors and other molecular targets. The aim of this review was to provide an overview of the endocannabinoid system and a summary of the clinical and preclinical findings of the therapeutic use of cannabinoids in epilepsy, multiple sclerosis and Parkinson’s disease, pointing out interactions with molecular targets and the potential for neuroprotection of CBD. Electronic searches were carried out in international databases, including studies that presented consistent data on this subject. Significant therapeutic effects of CBD were shown for epilepsy and Parkinson’s disease, while nabiximols contributed to the reduction of spasticity, being a frequent option for the treatment of multiple sclerosis. Although much has been projected on the therapeutic potential of cannabinoids for neurological disorders, there is a long way to go in the search for strong scientific evidence of their pharmacological effectiveness.
16 Oct 2023Submitted to Basic & Clinical Pharmacology & Toxicology
16 Oct 2023Submission Checks Completed
16 Oct 2023Assigned to Editor
16 Oct 2023Review(s) Completed, Editorial Evaluation Pending
17 Oct 2023Reviewer(s) Assigned
09 Nov 2023Editorial Decision: Revise Minor
25 Jan 2024Review(s) Completed, Editorial Evaluation Pending
26 Jan 2024Editorial Decision: Revise Minor
14 Feb 20243rd Revision Received
15 Feb 2024Submission Checks Completed
15 Feb 2024Assigned to Editor
16 Feb 2024Review(s) Completed, Editorial Evaluation Pending